17.59

1.79% 0.31

After Hours: 17.20 -0.39 -2.22%

Entrada Therapeutics Inc (TRDA)

Overview News Price History Financials Discussions Forecast

Entrada Therapeutics Inc stock is traded at $17.59, with a volume of 340.63K. It is up +1.79% in the last 24 hours and down -1.90% over the past month. Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Previous Close:

$17.28

Open:

$16.86

24h Volume:

340.63K

Relative Volume:

2.55

Market Cap:

$658.22M

Revenue:

$239.40M

Net Income/Loss:

$104.44M

P/E Ratio:

-6.8178

EPS:

-2.58

Net Cash Flow:

$-18.50M

1W Performance:

-0.40%

1M Performance:

-1.90%

6M Performance:

+21.81%

1Y Performance:

+17.34%

1-Day Range:

$16.86

$18.00

1-Week Range:

$16.86

$18.96

52-Week Range:

$11.35

$21.79

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name

Entrada Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

857-305-1825

Address

ONE DESIGN CENTER PLACE, BOSTON

Employee

177

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

TRDA's Discussions on Twitter

Compare TRDA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRDA Entrada Therapeutics Inc	17.59	658.22M	239.40M	104.44M	-18.50M	2.96
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	ROTH MKM	Buy
Jan-05-24	Initiated	Oppenheimer	Outperform
Apr-03-23	Initiated	H.C. Wainwright	Buy

Entrada Therapeutics Inc Stock (TRDA) Latest News

Dec 18, 2024

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com

Dec 18, 2024

Dec 17, 2024

(TRDA) Proactive Strategies - Stock Traders Daily

Dec 17, 2024

Dec 16, 2024

Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN

Dec 16, 2024

Dec 13, 2024

XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Dec 13, 2024

Dec 10, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat

Dec 10, 2024

Dec 09, 2024

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St

Dec 09, 2024

Dec 08, 2024

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World

Dec 08, 2024

Dec 07, 2024

Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat

Dec 07, 2024

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance

Dec 07, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat

Dec 07, 2024

Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Dec 07, 2024

Dec 03, 2024

Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com

Dec 03, 2024

Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria

Dec 03, 2024

Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria

Dec 03, 2024

Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India

Dec 03, 2024

Entrada Therapeutics president sells $320,619 in stock - Investing.com

Dec 03, 2024

Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada

Dec 03, 2024

Nov 28, 2024

Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 28, 2024

Nov 26, 2024

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Nov 26, 2024

(TRDA) Investment Analysis and Advice - Stock Traders Daily

Nov 26, 2024

Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 26, 2024

Nov 17, 2024

Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 17, 2024

Nov 15, 2024

Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

500: Something went wrong - Investing.com UK

Nov 13, 2024

Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada

Nov 13, 2024

Nov 11, 2024